Seminars in Nuclear Medicine
Volume 39, Issue 3 , Pages 204-209, May 2009

Current Advances in Vasodilator Pharmacological Stress Perfusion Imaging

  • Regina S. Druz, MD, FACC, FASNC

      Affiliations

    • Nuclear Cardiology, North Shore University Hospital, Manhasset, NY
    • New York University School of Medicine, New York, NY
    • Corresponding Author InformationAddress reprint requests to Regina S. Druz, MD, FACC, FASNC, Nuclear Cardiology, North Shore University Hospital, 300 Community Drive, Manhasset, NY 11030

More than 7 million stress perfusion studies are performed in the United States annually, 44% with pharmacological vasodilator stress agents. Both adenosine and dipyridamole are nonselective coronary vasodilators that are commonly used for stress perfusion imaging. These agents are safe and provide an effective means to diagnose coronary artery disease. A newer agent, regadenoson, is an adenosine receptor agonist that is selective for coronary vasodilation. Regadenoson is noninferior to adenosine for the detection of ischemia and is better tolerated by patients. Recent trials such as INSPIRE (Adenosine Sestamibi Post-Infarction Evaluation) and the COURAGE (Results from Clinical Outcomes Utilizing Revascularization and Aggressive Guideline-driven Drug Evaluation) Nuclear Imaging Substudy have established clearly that noninvasive risk stratification with vasodilator testing is an important and appropriate step in guiding medical therapy and invasive coronary intervention.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0001-2998(08)00139-6

doi:10.1053/j.semnuclmed.2008.12.003

Seminars in Nuclear Medicine
Volume 39, Issue 3 , Pages 204-209, May 2009